Search fresh public links, source activity, and ready-to-use post angles for Specialty Drugs.
Fresh curated links around Specialty Drugs are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
As specialty medicines play a growing role in healthcare, the patient journey that follows is equally critical.
The organizations that move now — with the right foundation and the right partners — will enter the next planning cycle with a specialty pharmacy that functions as a true strategic...
This week, we’re rerunning some popular posts while we prepare for tomorrow’s live video webinar: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders....
This week, we’re rerunning some popular posts while we prepare for Friday’s live video webinar: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders....
Today’s guest post comes from Nareda Mills, President of Patient Solutions at Inizio Engage. Nareda examines how growing access complexity is reshaping specialty commercializatio...
For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.
By Bryce Platt, PharmD Provider-administered drugs are one of the fastest-growing and least-managed cost drivers for commercial plan sponsors. Despite that, recent data from...
By Bryce Platt, PharmD Summer officially starts this weekend! Consider doing a few of your lifting sets (or work meetings) outside. The healthier you are, the longer you’l...
Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, including requiring the PBM to stop preferring higher cost ver...
By Bryce Platt, PharmD For years, Medicare Part D plans often preferred high-list/high-rebate branded multiple sclerosis (MS) drugs over lower-cost generics. That was rational b...
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Bruk...
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster” sal...
Today we’re diving into the world of corticosteroids and hormonal therapies, essential APIs that treat everything from asthma and autoimmune diseases to diabetes and endocrine diso...
Evernorth has unveiled a new specialty pharmacy program that leans on AI to support a better experience for patients with complex conditions.
New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its...
Orphan drugs remain commercially durable, strategically relevant and supported by a strong pipeline
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.